{
  "id": 6523725,
  "title": "HOYA Lens Singapore introduces MiYOSMART spectacle lens for pediatric myopia",
  "url": "https://urgent.news/2026/09/10/hoya-lens-singapore-introduces-miyosmart-spectacle-lens-for-pediatric",
  "topic": "business",
  "section": "Business",
  "published": "2026-09-10T02:34:51.000Z",
  "source": {
    "name": "Vietnam Investment Review",
    "slug": "vietnam-investment-review",
    "url": "https://vir.com.vn/hoya-lens-singapore-introduces-miyosmart-spectacle-lens-for-pediatric-myopia-160344.html"
  },
  "original_language": "en",
  "account": "HOYA Lens Singapore has unveiled its most advanced myopia control spectacle lens, MiYOSMART iQ TF, marking a significant advancement in the company's MiYOSMART platform. The new lens combines Defocus Incorporated Multiple Segments (D.I.M.S.) Technology with Triple Enhanced Design (TED) for superior myopia control effectiveness in children. Clinical trials have shown that 90% of children who wore MiYOSMART iQ TF for 12 months experienced no clinically relevant myopia progression. This breakthrough lens is the first to demonstrate myopia control efficacy in children as young as four years old. MiYOSMART iQ TF offers four options, including Clear Clear, Chameleon Photochromic, and HOYA Full Control Coating for added protection against UV rays and glare. With this innovative lens, HOYA Vision Care aims to manage early-onset myopia and provide children with a non-invasive solution for maintaining healthy vision.",
  "summary": "HOYA Lens Singapore launched its MiYOSMART iQTF spectacle lens integrating specialized optical technology designed to manage and slow down myopia progression in young children",
  "key_points": [
    "HOYA introduces MiYOSMART iQ TF, advanced myopia control lens",
    "90% of children in trials showed no myopia progression over 12 months",
    "First lens to control myopia in children as young as four"
  ],
  "editors_take": "HOYA Lens Singapore's MiYOSMART spectacle lens marks a significant advancement in pediatric myopia control, offering a non-invasive solution for children as young as four with superior effectiveness.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}